Thierauch, Prostaglandins and their Receptors: II. Receptor Structure and Signal Transduction, Journal of Hypertension, 12:1-5 (1994). |
Waterbury, et al., EP3 but not EP2 FP or TP Prostanoid-Receptor Stimulation May Reduce Intraocular Pressure, Investigative Ophthalmology and Visual Science, 31(12):2560-2567 (1990). |
Woodward, et al., Molecular Characterization and Ocular Hypotensive Properties of the Prostaglandin EP2 Receptor Journal of Ocular Pharmacology and Therapeutics, 11(3):447-454 (1995). |
Alm, The Potential of Prostaglandin Derivatives in Glaucoma Therapy, Current Opinion in Ophthalmology, 4(11):44-50 (1993). |
Bito et al., The Ocular Effects of Prostaglandins and the Therapeutic Potential of A New PGF2αAnalog, PhXA41 (latanoprost), for Glaucoma Management, J. of Lipid Mediators, 6:535-543 (1993). |
Flach et al., Topical Prostaglandin E2 Effects on Normal Human Intraocular Pressure Journal of Ocular Pharmacology, 4(1):13-18 (1988). |
Giuffre, The Effects of Prostaglandin F2αthe Human Eye, Graefe's Archive Ophthalmology, 222:139-141 (1985). |
Ichikawa et al., Molecular Aspects of the Structures and Functions of the Prostaglandin E Receptors, J. Lipid Mediators Cell Signaling, 14:83-87 (1996). |
Kerstetter et al., Prostaglandin F2α-1-Isopropylester Lowers Intraocular Pressure Without Decreasing Aqueous Humor Flow, American Journal of Ophthalmology, 105:30-34 (1988). |
Mjalli et al., Synthesis of Some 13-Oxaprostaglandoids, J. Chem. Soc. Perkin Trans I, 2105-2109 (1989). |
Nakajima, Effects of Prostaglandin D2 and its analogue, BW245C, on Intraocular Pressure in Humans, Graefe's Archive Ophthalmology, 229:411-413 (1991). |
New research Drug DLO/8149, Drug License Opportunities (IMSWORLD Publications) (June 25, 1990). |